It is indicated as an adjuvant (after surgery) treatment for HER2+ early breast cancer in patients who previously received trastuzumab (Herceptin®) and a taxane, separately or in combination [66,67,68,69]. The gene discussed is ERBB2; the disease is breast cancer.